Trial site
Natalie Warren Bryant Cancer Center at Saint Francis
Tulsa, Oklahoma 74136, United StatesNot linked to an institution yet
- 2running trials
- 16closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 21 trial
- Status
- Completed16 trials
- Active, not recruiting1 trial
- Recruiting1 trial
- Lead sponsor
- National Cancer Institute (NCI)8 trials
- Children's Oncology Group7 trials
- Alliance for Clinical Trials in Oncology1 trial
- Radiation Therapy Oncology Group1 trial
- SWOG Cancer Research Network1 trial
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02003209· Phase 3· National Cancer Institute (NCI)· Source
Completed
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT01708941· Phase 2· National Cancer Institute (NCI)· Source
Completed
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
NCT01546987· Phase 3· Radiation Therapy Oncology Group· Source
Completed
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
NCT02883049· Phase 3· National Cancer Institute (NCI)· Source
Completed
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
NCT01120249· Phase 3· SWOG Cancer Research Network· Source
Completed
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
NCT01231906· Phase 3· Children's Oncology Group· Source
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
NCT01190930· Phase 3· Children's Oncology Group· Source
Completed
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01013649· Phase 3· National Cancer Institute (NCI)· Source
Completed
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00601900· Phase 3· National Cancer Institute (NCI)· Source
Completed
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source
Completed
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805· Phase 3· National Cancer Institute (NCI)· Source
Completed
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
NCT00379340· Phase 3· Children's Oncology Group· Source
Completed
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00408005· Phase 3· National Cancer Institute (NCI)· Source
Completed
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
NCT00352534· Phase 3· Children's Oncology Group· Source
Completed
Study of Kidney Tumors in Younger Patients
NCT00898365· Children's Oncology Group· Source
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241· Children's Oncology Group· Source
Report an error